Search

In this article, the author comments on an article by J. Weng on the application of an off-the-shelf approach targeting a common antigen on malignant B cells while idiotype vaccines have shown promise for B-cell malignancies. The potential for an off-the-shelf vaccine for lymphomas is offered by the identification of a common antigen on B-cell malignancies that is not present on normal B cells.